HIV Risk Clinical Trial
Official title:
Evaluation of Compliance With Treatment by Elvitegravir/Cobicistat/FTC/Tenofovir Alafenamide (E/C/F/TAF) in HIV Post-exposure Prophylaxis (to Infected Blood or Sexual Contact)
This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Genvoya for four weeks
This study measures the proportion of enrolled patients taking the uninterrupted HIV
post-exposure prophylaxis Elvitegravir/Cobicistat/FTC/Tenofovir alafenamide (E/C/F/TAF) for
four Weeks.
Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Cobicistat is a
selective, mechanism-based inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A subfamily.
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue
àf 2'-dexicytidine. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor
(NtRTI) and phosphonoamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02112201 -
The ProGirls Study
|
N/A | |
Completed |
NCT03664362 -
The BSHAPE Intervention Program for Safety and Health of Survivors of Cumulative Trauma
|
N/A | |
Withdrawn |
NCT01381146 -
Victim Impact Modules for Jail Inmates
|
N/A | |
Completed |
NCT01866046 -
Rapid HIV Testing and Counseling in High Risk Women in Shelters
|
Phase 1 | |
Active, not recruiting |
NCT01378936 -
Jail-Based Impact of Crime Intervention
|
Phase 2 | |
Active, not recruiting |
NCT01380977 -
Trial of Impact of Crime Group Intervention for Jail Inmates
|
Phase 1/Phase 2 | |
Recruiting |
NCT05368571 -
CHOICES-TEEN Randomized Controlled Trial
|
N/A | |
Completed |
NCT02611362 -
A Multilevel Gaming Intervention for Persons on PrEP
|
N/A | |
Completed |
NCT04718194 -
Developing Online Interventions to Reduce Stigma-Related Stress, Sexual Health, and HIV Risk Among Young Chinese MSM
|
N/A | |
Not yet recruiting |
NCT05828849 -
Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk
|
N/A |